Editorial: Exploration of platinum-induced neuropathy should be based on both objective and subjective examinations

Acta Oncologica

Volumn 48, Issue 6, 2009, Pages 804-806

  Oldenburg, Jan ^a,b   Foss, Sophie D ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CISPLATIN; GLUTATHIONE TRANSFERASE; MORPHINE; OXALIPLATIN; PLATINUM COMPLEX; TRICYCLIC ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; DNA POLYMORPHISM; EDITORIAL; GENETIC SUSCEPTIBILITY; HEARING IMPAIRMENT; HUMAN; LUNG CANCER; NEUROPATHY; NEUROTOXICITY; PARESTHESIA; PERSONALITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RISK FACTOR; TESTIS CANCER; TINNITUS; CHEMICALLY INDUCED DISORDER; NOTE; PERIPHERAL NEUROPATHY;

ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 70350643869     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860902984729     Document Type: Editorial

References (22)

1. Fossa SD. Long-term sequelae after cancer therapy - Survivorship after treatment for testicular cancer. Acta Oncol 2004;/43:/134-41.
2. Nord C, Ganz PA, Aziz N, Fossa SD. Follow-up of longterm cancer survivors in the Nordic countries. Acta Oncol 2007;/46:/433-40.
3. O'Dwyer PJ, Eckhardt SG, Haller DG, Tepper J, Ahnen D, Hamilton S, et al. Priorities in colorectal cancer research: Recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. J Clin Oncol 2007;/25:/2313-21.
4. Brouwers E, Huitema A, Boogerd W, Beijnen J, Schellens J. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol 2009 (in press).
5. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;/33:/15-49.
6. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltagegated sodium channels. Br J Pharmacol 2005;/146:/1027-39.
7. Meijer C, de Vries EGE, Marmiroli P, Tredici G, Frattola L, Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999;/20:/883-7.
8. McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001;/85:/1219-25.
9. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity 195. Neurobiol Dis 2005;/18:/305-13.
10. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile(105)Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006;/12:/ 3050-6.
11. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;/25:/708-14.
12. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neurotoxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007;/5:/70.
13. Shukla SJ, Duan S, Badner JA, Wu XL, Dolan ME. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics 2008;/18:/253-62.
14. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003;/61:/1297-300.
15. Jensen K. Measuring side effects after radiotherapy for pharynx cancer. Acta Oncol 2007;/46:/1051-63.
16. Ebenezer GJ, Hauer P, Gibbons C, McArthur JC, Polydefkis M. Assessment of epidermal nerve fibers: A new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol 2007;/66:/1059-73.
17. Gibbons CH, Illigens BM, Centi J, Freeman R. QDIRT: Quantitative direct and indirect test of sudomotor function. Neurology 2008;/70:/2299-304.
18. Grov EK, Dahl AA, Fossa SD.Neuroticism. Acta Oncol 2009 (in press).
19. Knap MM, Bentzen SM, Overgaard J. Late neurological complications after irradiation of malignant tumors of the testis. Acta Oncol 2007;/46:/497-503.
20. Brydoy M, Storstein A, Dahl O. Transient neurological adverse effects following low dose radiation therapy for early stage testicular seminoma. Radiother Oncol 2007;/82:/ 137-44.
21. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical 2008 Oncology clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;/27:/127-45.
22. Kaley TJ Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009.